视网膜下而非玻璃体腔AAV递送补体替代途径抑制剂在RPE损伤小鼠模型中有效
该研究在烟雾诱导眼病模型(SIOP,类似干性AMD)中比较了两种AAV载体:AAV5-VMD2-CR2-fH靶向RPE,AAV2YF-smCBA-CR2-fH靶向视网膜神经节细胞(RGC)。结果显示仅RPE介导的CR2-fH分泌能减少SIOP和RPE/脉络膜补体激活,且CR2-fH跨RPE转运效率低且依赖ATP。结论提示补体抑制需在RPE基底侧发挥作用,支持通过AAV将药物递送至RPE或血视网膜屏障外。
要点
- 仅靶向RPE的AAV5-VMD2-CR2-fH可减少SIOP模型中的补体激活和病理改变。
- 靶向RGC的AAV2YF-smCBA-CR2-fH无效,提示递送位置决定疗效。
- CR2-fH跨RPE转运效率低且依赖ATP,可能影响玻璃体腔给药效果。
核心结论
- 针对AMD样病理的补体抑制需要在RPE基底侧发挥作用。
- 支持通过AAV将补体抑制剂递送至RPE或血视网膜屏障外。
研究设计与样本
- 在烟雾诱导眼病模型(SIOP,6个月被动吸烟)中比较两种AAV载体:AAV5-VMD2-CR2-fH靶向RPE,AAV2YF-smCBA-CR2-fH靶向RGC。
- 评估视觉功能(视动反应)、视网膜结构(OCT)及RPE和Bruch膜完整性(电镜),并用蛋白质化学方法检测补体激活、CR2-fH组织分布及跨RPE转运。
主要发现
- RPE介导的CR2-fH分泌减少SIOP和RPE/脉络膜补体激活,而RGC介导的分泌无效。
- 仅在AAV5-VMD2-CR2-fH处理后可在RPE/脉络膜中确认CR2-fH生物可利用性。
- CR2-fH跨RPE转运效率低且依赖三磷酸腺苷(ATP)。
临床怎么用
- 对于AMD样补体介导的RPE损伤,AAV载体应靶向RPE而非RGC。
- 玻璃体腔给药可能因CR2-fH跨RPE转运效率低而受限,需考虑视网膜下或屏障外递送。
局限性
- 研究仅基于小鼠SIOP模型,结论外推到人类AMD需谨慎。
- 未报告临床剂量、安全性及长期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The risk for age-related macular degeneration has been tied to an overactive complement system. Despite combined attempts by academia and industry to develop therapeutics that modulate the complement response, particularly in the late geographic atrophy form of advanced AMD, to date, there is no effective treatment. We have previously demonstrated that pathology in the smoke-induced ocular pathology (SIOP) model, a model with similarities to dry AMD, is dependent on activation of the alternative complement pathway and that a novel complement activation site targeted inhibitor of the alternative pathway can be delivered to ocular tissues via an adeno-associated virus (AAV). METHODS: Two different viral vectors for specific tissue targeting were compared: AAV5-VMD2-CR2-fH for delivery to the retinal pigment epithelium (RPE) and AAV2YF-smCBA-CR2-fH for delivery to retinal ganglion cells (RGCs). Efficacy was tested in SIOP (6 months of passive smoke inhalation), assessing visual function (optokinetic responses), retinal structure (optical coherence tomography), and integrity of the RPE and Bruch's membrane (electron microscopy). Protein chemistry was used to assess complement activation, CR2-fH tissue distribution, and CR2-fH transport across the RPE. RESULTS: RPE- but not RGC-mediated secretion of CR2-fH was found to reduce SIOP and complement activation in RPE/choroid. Bioavailability of CR2-fH in RPE/choroid could be confirmed only after AAV5-VMD2-CR2-fH treatment, and inefficient, adenosine triphosphate-dependent transport of CR2-fH across the RPE was identified. CONCLUSIONS: Our results suggest that complement inhibition for AMD-like pathology is required basal to the RPE and argues in favor of AAV vector delivery to the RPE or outside the blood-retina barrier.
引用
- Annamalai B, Parsons N, Nicholson C, et al. Subretinal Rather Than Intravitreal Adeno-Associated Virus-Mediated Delivery of a Complement Alternative Pathway Inhibitor Is Effective in a Mouse Model of RPE Damage. Invest Ophthalmol Vis Sci. 2021. PMID: 33830174. doi:10.1167/iovs.62.4.11
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。